NYSE:NVO

Novo Nordisk A/s Stock News

Healthcare > Biotechnology

Buy NVO

*Your capital is at risk

$47.64

+0.230 (+0.485%)

At Close: Jun 25, 2026

Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)

11:45am, Wednesday, 05'th Feb 2025

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity highligh

Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

11:45am, Wednesday, 05'th Feb 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws

Novo Nordisk gains on Q4 earnings beat

11:31am, Wednesday, 05'th Feb 2025

Novo Nordisk (NYSE:NVO) shares moved higher as the Danish drugmaker posted better-than-expected financial results for the fourth quarter driven by demand for its obesity drugs. The company posted

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

11:13am, Wednesday, 05'th Feb 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acq

Novo Nordisk A/S Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Investors With Losses To Reach Out

11:00am, Wednesday, 05'th Feb 2025

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo"

Novo Nordisk Stock Pops on Upbeat Earnings

10:58am, Wednesday, 05'th Feb 2025

Pharmaceutical concern Novo Nordisk A/S (NYSE:NVO) is up 4.9% at $86.63 at last glance.

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO

10:30am, Wednesday, 05'th Feb 2025

UBER's Autonomous Uncertainty, CMG Slips & NVO Rises on Earnings

10:15am, Wednesday, 05'th Feb 2025

George Tsilis offers a macro market perspective by noting long-term upside that will come with sideways chop. On stock movers, Chipotle (CMG) is trading down after a slip in its restaurant level opera

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

10:13am, Wednesday, 05'th Feb 2025

Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The company's GLP-1 drugs, Ozempic and W

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

10:00am, Wednesday, 05'th Feb 2025

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

NVO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

10:00am, Wednesday, 05'th Feb 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nor

Amid Novo Nordisk's Win for Ozempic's Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists' Rising Influence in GLP-1 RA Utilization

09:33am, Wednesday, 05'th Feb 2025

Analysis of over 1,000 chronic kidney disease patient charts shows GLP-1 receptor agonist use nearly doubling from 2023 to 2024. Analysis of over 1,000 chronic kidney disease patient charts shows GLP-

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by